Edition:
United States

Axim Biotechnologies announces phase IIa trial results validating its proprietary cannabinoid delivery method


Tuesday, 21 Nov 2017 09:00am EST 

Nov 21 (Reuters) - Axim Biotechnologies Inc ::Announces phase IIa trial results validating its proprietary cannabinoid delivery method for treatment of irritable bowel syndrome (IBS).Study results indicate that CanChew+ was well tolerated by IBS patients and no significant adverse side effects were observed by any participants of trial​. 

Company Quote

1.2
-0.06 -4.76%
3:50pm EST